Eintrag weiter verarbeiten
First-in-human phase 1 PET study of CTT1057, a novel 18F-labeled imaging agent targeting prostate specific membrane antigen (PSMA) in prostate cancer.
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , |
| In: | Journal of Clinical Oncology, 35, 2017, 15_suppl, S. e16562-e16562 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Aggarwal, Rahul Raj Behr, Spencer Seo, Youngho Gao, Kenneth Rahanfar, Vahid Slater, Jim Blecha, Joseph Langton-Webster, Beatrice Berkman, Clifford Vanbrocklin, Henry Aggarwal, Rahul Raj Behr, Spencer Seo, Youngho Gao, Kenneth Rahanfar, Vahid Slater, Jim Blecha, Joseph Langton-Webster, Beatrice Berkman, Clifford Vanbrocklin, Henry |
|---|---|
| author |
Aggarwal, Rahul Raj Behr, Spencer Seo, Youngho Gao, Kenneth Rahanfar, Vahid Slater, Jim Blecha, Joseph Langton-Webster, Beatrice Berkman, Clifford Vanbrocklin, Henry |
| spellingShingle |
Aggarwal, Rahul Raj Behr, Spencer Seo, Youngho Gao, Kenneth Rahanfar, Vahid Slater, Jim Blecha, Joseph Langton-Webster, Beatrice Berkman, Clifford Vanbrocklin, Henry Journal of Clinical Oncology First-in-human phase 1 PET study of CTT1057, a novel 18F-labeled imaging agent targeting prostate specific membrane antigen (PSMA) in prostate cancer. Cancer Research Oncology |
| author_sort |
aggarwal, rahul raj |
| spelling |
Aggarwal, Rahul Raj Behr, Spencer Seo, Youngho Gao, Kenneth Rahanfar, Vahid Slater, Jim Blecha, Joseph Langton-Webster, Beatrice Berkman, Clifford Vanbrocklin, Henry 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e16562 <jats:p> e16562 </jats:p><jats:p> Background: Urea-based <jats:sup>68</jats:sup>Ga-PSMA PET is increasingly being utilized for diagnostic purposes in prostate cancer; however high tracer uptake within the salivary gland and kidney may be dose-limiting upon translation to radiotherapy. We developed a novel <jats:sup>18</jats:sup>F labeled agent, CTT1057, a PSMA inhibitor based on a phosphoramidate scaffold with nanomolar and irreversible binding affinity to PSMA and robust internalization, and performed a first-in-human imaging study. Methods: Patients (pts) with metastatic castration resistant prostate cancer (mCRPC) were eligible. 10 mCi (370 MBq) of CTT1057 was injected and whole body PET/MR imaging (SIGNA PET/MR, GE) was performed 60 min post-injection. SUV<jats:sub>mean</jats:sub> in normal organs was recorded by drawing a 1 cm<jats:sup>3</jats:sup> volume-of-interest. SUV<jats:sub>max</jats:sub> was determined for each PSMA-avid metastasis. 10 randomly selected, consecutive <jats:sup>68</jats:sup>Ga-PSMA PET scans from an independent cohort were used for descriptive comparison. Results: 5 pts with mCRPC were enrolled, with average age of 66 years (range 35–85) and median PSA of 12.2 (range 0.73 – 157.7). 55 PSMA-avid metastases were seen, including 37 osseous (average SUV<jats:sub>max</jats:sub> = 8.1 ± 4.4), 15 lymph node (SUV<jats:sub>max</jats:sub> = 11.0 ± 6.1), and 3 pulmonary (SUV<jats:sub>max</jats:sub> = 3.2 ± 0.6). 31 (83%) and 12 (32%) of the PSMA-avid osseous lesions were visible on CT and bone scan, respectively. The mean short axis diameter of PSMA-avid lymph nodes was 0.7 ± 0.4 cm. Tumor-to-background ratios (liver, muscle, blood pool) were 2.8 ± 2.3, 14.9 ± 11.6, and 3.2 ± 2.4, respectively. SUV<jats:sub>mean</jats:sub> in salivary gland and kidney were 3.6 ± 0.4 and 9.1 ± 0.8 for CTT1057 and 15.8 ± 2.7 and 35.9 ± 9.6 for <jats:sup>68</jats:sup>Ga-PSMA, respectively. No tracer-related adverse events were observed and radiation dose estimates for organs and whole-body effective dose were within acceptable limits. Conclusions: <jats:sup>18</jats:sup>F-labeled CTT1057 targeting PSMA, detected mCRPC lesions in the soft tissue and bone at greater sensitivity than conventional imaging. CTT1057 distribution of uptake was similar to urea-based PSMA imaging, with preliminary evidence of lower uptake in the salivary gland and kidney. Further clinical studies of the CTT1057 backbone as a diagnostic and therapeutic agent in mCRPC are warranted. Clinical trial information: NCT02916537. </jats:p> First-in-human phase 1 PET study of CTT1057, a novel <sup>18</sup>F-labeled imaging agent targeting prostate specific membrane antigen (PSMA) in prostate cancer. Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2017.35.15_suppl.e16562 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxNy4zNS4xNV9zdXBwbC5lMTY1NjI |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxNy4zNS4xNV9zdXBwbC5lMTY1NjI |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Society of Clinical Oncology (ASCO), 2017 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2017 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
aggarwal2017firstinhumanphase1petstudyofctt1057anovel18flabeledimagingagenttargetingprostatespecificmembraneantigenpsmainprostatecancer |
| publishDateSort |
2017 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
First-in-human phase 1 PET study of CTT1057, a novel 18F-labeled imaging agent targeting prostate specific membrane antigen (PSMA) in prostate cancer. |
| title_unstemmed |
First-in-human phase 1 PET study of CTT1057, a novel 18F-labeled imaging agent targeting prostate specific membrane antigen (PSMA) in prostate cancer. |
| title_full |
First-in-human phase 1 PET study of CTT1057, a novel 18F-labeled imaging agent targeting prostate specific membrane antigen (PSMA) in prostate cancer. |
| title_fullStr |
First-in-human phase 1 PET study of CTT1057, a novel 18F-labeled imaging agent targeting prostate specific membrane antigen (PSMA) in prostate cancer. |
| title_full_unstemmed |
First-in-human phase 1 PET study of CTT1057, a novel 18F-labeled imaging agent targeting prostate specific membrane antigen (PSMA) in prostate cancer. |
| title_short |
First-in-human phase 1 PET study of CTT1057, a novel 18F-labeled imaging agent targeting prostate specific membrane antigen (PSMA) in prostate cancer. |
| title_sort |
first-in-human phase 1 pet study of ctt1057, a novel <sup>18</sup>f-labeled imaging agent targeting prostate specific membrane antigen (psma) in prostate cancer. |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e16562 |
| publishDate |
2017 |
| physical |
e16562-e16562 |
| description |
<jats:p> e16562 </jats:p><jats:p> Background: Urea-based <jats:sup>68</jats:sup>Ga-PSMA PET is increasingly being utilized for diagnostic purposes in prostate cancer; however high tracer uptake within the salivary gland and kidney may be dose-limiting upon translation to radiotherapy. We developed a novel <jats:sup>18</jats:sup>F labeled agent, CTT1057, a PSMA inhibitor based on a phosphoramidate scaffold with nanomolar and irreversible binding affinity to PSMA and robust internalization, and performed a first-in-human imaging study. Methods: Patients (pts) with metastatic castration resistant prostate cancer (mCRPC) were eligible. 10 mCi (370 MBq) of CTT1057 was injected and whole body PET/MR imaging (SIGNA PET/MR, GE) was performed 60 min post-injection. SUV<jats:sub>mean</jats:sub> in normal organs was recorded by drawing a 1 cm<jats:sup>3</jats:sup> volume-of-interest. SUV<jats:sub>max</jats:sub> was determined for each PSMA-avid metastasis. 10 randomly selected, consecutive <jats:sup>68</jats:sup>Ga-PSMA PET scans from an independent cohort were used for descriptive comparison. Results: 5 pts with mCRPC were enrolled, with average age of 66 years (range 35–85) and median PSA of 12.2 (range 0.73 – 157.7). 55 PSMA-avid metastases were seen, including 37 osseous (average SUV<jats:sub>max</jats:sub> = 8.1 ± 4.4), 15 lymph node (SUV<jats:sub>max</jats:sub> = 11.0 ± 6.1), and 3 pulmonary (SUV<jats:sub>max</jats:sub> = 3.2 ± 0.6). 31 (83%) and 12 (32%) of the PSMA-avid osseous lesions were visible on CT and bone scan, respectively. The mean short axis diameter of PSMA-avid lymph nodes was 0.7 ± 0.4 cm. Tumor-to-background ratios (liver, muscle, blood pool) were 2.8 ± 2.3, 14.9 ± 11.6, and 3.2 ± 2.4, respectively. SUV<jats:sub>mean</jats:sub> in salivary gland and kidney were 3.6 ± 0.4 and 9.1 ± 0.8 for CTT1057 and 15.8 ± 2.7 and 35.9 ± 9.6 for <jats:sup>68</jats:sup>Ga-PSMA, respectively. No tracer-related adverse events were observed and radiation dose estimates for organs and whole-body effective dose were within acceptable limits. Conclusions: <jats:sup>18</jats:sup>F-labeled CTT1057 targeting PSMA, detected mCRPC lesions in the soft tissue and bone at greater sensitivity than conventional imaging. CTT1057 distribution of uptake was similar to urea-based PSMA imaging, with preliminary evidence of lower uptake in the salivary gland and kidney. Further clinical studies of the CTT1057 backbone as a diagnostic and therapeutic agent in mCRPC are warranted. Clinical trial information: NCT02916537. </jats:p> |
| container_issue |
15_suppl |
| container_start_page |
0 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
35 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792326002027790352 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T12:14:33.042Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=First-in-human+phase+1+PET+study+of+CTT1057%2C+a+novel+18F-labeled+imaging+agent+targeting+prostate+specific+membrane+antigen+%28PSMA%29+in+prostate+cancer.&rft.date=2017-05-20&genre=article&issn=1527-7755&volume=35&issue=15_suppl&pages=e16562-e16562&jtitle=Journal+of+Clinical+Oncology&atitle=First-in-human+phase+1+PET+study+of+CTT1057%2C+a+novel+%3Csup%3E18%3C%2Fsup%3EF-labeled+imaging+agent+targeting+prostate+specific+membrane+antigen+%28PSMA%29+in+prostate+cancer.&aulast=Vanbrocklin&aufirst=Henry&rft_id=info%3Adoi%2F10.1200%2Fjco.2017.35.15_suppl.e16562&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792326002027790352 |
| author | Aggarwal, Rahul Raj, Behr, Spencer, Seo, Youngho, Gao, Kenneth, Rahanfar, Vahid, Slater, Jim, Blecha, Joseph, Langton-Webster, Beatrice, Berkman, Clifford, Vanbrocklin, Henry |
| author_facet | Aggarwal, Rahul Raj, Behr, Spencer, Seo, Youngho, Gao, Kenneth, Rahanfar, Vahid, Slater, Jim, Blecha, Joseph, Langton-Webster, Beatrice, Berkman, Clifford, Vanbrocklin, Henry, Aggarwal, Rahul Raj, Behr, Spencer, Seo, Youngho, Gao, Kenneth, Rahanfar, Vahid, Slater, Jim, Blecha, Joseph, Langton-Webster, Beatrice, Berkman, Clifford, Vanbrocklin, Henry |
| author_sort | aggarwal, rahul raj |
| container_issue | 15_suppl |
| container_start_page | 0 |
| container_title | Journal of Clinical Oncology |
| container_volume | 35 |
| description | <jats:p> e16562 </jats:p><jats:p> Background: Urea-based <jats:sup>68</jats:sup>Ga-PSMA PET is increasingly being utilized for diagnostic purposes in prostate cancer; however high tracer uptake within the salivary gland and kidney may be dose-limiting upon translation to radiotherapy. We developed a novel <jats:sup>18</jats:sup>F labeled agent, CTT1057, a PSMA inhibitor based on a phosphoramidate scaffold with nanomolar and irreversible binding affinity to PSMA and robust internalization, and performed a first-in-human imaging study. Methods: Patients (pts) with metastatic castration resistant prostate cancer (mCRPC) were eligible. 10 mCi (370 MBq) of CTT1057 was injected and whole body PET/MR imaging (SIGNA PET/MR, GE) was performed 60 min post-injection. SUV<jats:sub>mean</jats:sub> in normal organs was recorded by drawing a 1 cm<jats:sup>3</jats:sup> volume-of-interest. SUV<jats:sub>max</jats:sub> was determined for each PSMA-avid metastasis. 10 randomly selected, consecutive <jats:sup>68</jats:sup>Ga-PSMA PET scans from an independent cohort were used for descriptive comparison. Results: 5 pts with mCRPC were enrolled, with average age of 66 years (range 35–85) and median PSA of 12.2 (range 0.73 – 157.7). 55 PSMA-avid metastases were seen, including 37 osseous (average SUV<jats:sub>max</jats:sub> = 8.1 ± 4.4), 15 lymph node (SUV<jats:sub>max</jats:sub> = 11.0 ± 6.1), and 3 pulmonary (SUV<jats:sub>max</jats:sub> = 3.2 ± 0.6). 31 (83%) and 12 (32%) of the PSMA-avid osseous lesions were visible on CT and bone scan, respectively. The mean short axis diameter of PSMA-avid lymph nodes was 0.7 ± 0.4 cm. Tumor-to-background ratios (liver, muscle, blood pool) were 2.8 ± 2.3, 14.9 ± 11.6, and 3.2 ± 2.4, respectively. SUV<jats:sub>mean</jats:sub> in salivary gland and kidney were 3.6 ± 0.4 and 9.1 ± 0.8 for CTT1057 and 15.8 ± 2.7 and 35.9 ± 9.6 for <jats:sup>68</jats:sup>Ga-PSMA, respectively. No tracer-related adverse events were observed and radiation dose estimates for organs and whole-body effective dose were within acceptable limits. Conclusions: <jats:sup>18</jats:sup>F-labeled CTT1057 targeting PSMA, detected mCRPC lesions in the soft tissue and bone at greater sensitivity than conventional imaging. CTT1057 distribution of uptake was similar to urea-based PSMA imaging, with preliminary evidence of lower uptake in the salivary gland and kidney. Further clinical studies of the CTT1057 backbone as a diagnostic and therapeutic agent in mCRPC are warranted. Clinical trial information: NCT02916537. </jats:p> |
| doi_str_mv | 10.1200/jco.2017.35.15_suppl.e16562 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxNy4zNS4xNV9zdXBwbC5lMTY1NjI |
| imprint | American Society of Clinical Oncology (ASCO), 2017 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2017 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T12:14:33.042Z |
| match_str | aggarwal2017firstinhumanphase1petstudyofctt1057anovel18flabeledimagingagenttargetingprostatespecificmembraneantigenpsmainprostatecancer |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | e16562-e16562 |
| publishDate | 2017 |
| publishDateSort | 2017 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Aggarwal, Rahul Raj Behr, Spencer Seo, Youngho Gao, Kenneth Rahanfar, Vahid Slater, Jim Blecha, Joseph Langton-Webster, Beatrice Berkman, Clifford Vanbrocklin, Henry 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e16562 <jats:p> e16562 </jats:p><jats:p> Background: Urea-based <jats:sup>68</jats:sup>Ga-PSMA PET is increasingly being utilized for diagnostic purposes in prostate cancer; however high tracer uptake within the salivary gland and kidney may be dose-limiting upon translation to radiotherapy. We developed a novel <jats:sup>18</jats:sup>F labeled agent, CTT1057, a PSMA inhibitor based on a phosphoramidate scaffold with nanomolar and irreversible binding affinity to PSMA and robust internalization, and performed a first-in-human imaging study. Methods: Patients (pts) with metastatic castration resistant prostate cancer (mCRPC) were eligible. 10 mCi (370 MBq) of CTT1057 was injected and whole body PET/MR imaging (SIGNA PET/MR, GE) was performed 60 min post-injection. SUV<jats:sub>mean</jats:sub> in normal organs was recorded by drawing a 1 cm<jats:sup>3</jats:sup> volume-of-interest. SUV<jats:sub>max</jats:sub> was determined for each PSMA-avid metastasis. 10 randomly selected, consecutive <jats:sup>68</jats:sup>Ga-PSMA PET scans from an independent cohort were used for descriptive comparison. Results: 5 pts with mCRPC were enrolled, with average age of 66 years (range 35–85) and median PSA of 12.2 (range 0.73 – 157.7). 55 PSMA-avid metastases were seen, including 37 osseous (average SUV<jats:sub>max</jats:sub> = 8.1 ± 4.4), 15 lymph node (SUV<jats:sub>max</jats:sub> = 11.0 ± 6.1), and 3 pulmonary (SUV<jats:sub>max</jats:sub> = 3.2 ± 0.6). 31 (83%) and 12 (32%) of the PSMA-avid osseous lesions were visible on CT and bone scan, respectively. The mean short axis diameter of PSMA-avid lymph nodes was 0.7 ± 0.4 cm. Tumor-to-background ratios (liver, muscle, blood pool) were 2.8 ± 2.3, 14.9 ± 11.6, and 3.2 ± 2.4, respectively. SUV<jats:sub>mean</jats:sub> in salivary gland and kidney were 3.6 ± 0.4 and 9.1 ± 0.8 for CTT1057 and 15.8 ± 2.7 and 35.9 ± 9.6 for <jats:sup>68</jats:sup>Ga-PSMA, respectively. No tracer-related adverse events were observed and radiation dose estimates for organs and whole-body effective dose were within acceptable limits. Conclusions: <jats:sup>18</jats:sup>F-labeled CTT1057 targeting PSMA, detected mCRPC lesions in the soft tissue and bone at greater sensitivity than conventional imaging. CTT1057 distribution of uptake was similar to urea-based PSMA imaging, with preliminary evidence of lower uptake in the salivary gland and kidney. Further clinical studies of the CTT1057 backbone as a diagnostic and therapeutic agent in mCRPC are warranted. Clinical trial information: NCT02916537. </jats:p> First-in-human phase 1 PET study of CTT1057, a novel <sup>18</sup>F-labeled imaging agent targeting prostate specific membrane antigen (PSMA) in prostate cancer. Journal of Clinical Oncology |
| spellingShingle | Aggarwal, Rahul Raj, Behr, Spencer, Seo, Youngho, Gao, Kenneth, Rahanfar, Vahid, Slater, Jim, Blecha, Joseph, Langton-Webster, Beatrice, Berkman, Clifford, Vanbrocklin, Henry, Journal of Clinical Oncology, First-in-human phase 1 PET study of CTT1057, a novel 18F-labeled imaging agent targeting prostate specific membrane antigen (PSMA) in prostate cancer., Cancer Research, Oncology |
| title | First-in-human phase 1 PET study of CTT1057, a novel 18F-labeled imaging agent targeting prostate specific membrane antigen (PSMA) in prostate cancer. |
| title_full | First-in-human phase 1 PET study of CTT1057, a novel 18F-labeled imaging agent targeting prostate specific membrane antigen (PSMA) in prostate cancer. |
| title_fullStr | First-in-human phase 1 PET study of CTT1057, a novel 18F-labeled imaging agent targeting prostate specific membrane antigen (PSMA) in prostate cancer. |
| title_full_unstemmed | First-in-human phase 1 PET study of CTT1057, a novel 18F-labeled imaging agent targeting prostate specific membrane antigen (PSMA) in prostate cancer. |
| title_short | First-in-human phase 1 PET study of CTT1057, a novel 18F-labeled imaging agent targeting prostate specific membrane antigen (PSMA) in prostate cancer. |
| title_sort | first-in-human phase 1 pet study of ctt1057, a novel <sup>18</sup>f-labeled imaging agent targeting prostate specific membrane antigen (psma) in prostate cancer. |
| title_unstemmed | First-in-human phase 1 PET study of CTT1057, a novel 18F-labeled imaging agent targeting prostate specific membrane antigen (PSMA) in prostate cancer. |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e16562 |